Moma Therapeutics is continuing the development of Antares’ next-generation, brain-penetrant, selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989, as …

Antares Therapeutics Biotechnology Research Transforming patient lives through pioneering precision medicines About us Website https://www.antaresrx.com Industry Biotechnology …

Jun 10, 2025 · Antares is a spin-out of Scorpion Therapeutics, Inc. (“Scorpion”), which sold its mutant-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company (“Lilly”) in March …

Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other …

Information on valuation, funding, cap tables, investors, and executives for Antares Therapeutics. Use the PitchBook Platform to explore the full profile.

Dec 24, 2025 · Country: USA | Funding: $177M (+) Website: https://antaresrx.com/ Antares is a biotechnology company focused on developing transformational,medicines targeting validated …

Jun 10, 2025 · Boston, Mass. — A new biotechnology company, Antares Therapeutics, has launched with $177 million in Series A financing to develop precision medicines targeting …

Jun 17, 2025 · Antares Therapeutics - a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases - launched with $177 million in Series A …

Jun 10, 2025 · Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and …

Jun 10, 2025 · NEW YORK – Antares Therapeutics, a spinoff of Scorpion Therapeutics, launched Tuesday to develop precision medicines for cancer and other diseases. The launch of Antares …